Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Cellectis patents


Recent patent applications related to Cellectis. Cellectis is listed as an Agent/Assignee. Note: Cellectis may have other listings under different names/spellings. We're not affiliated with Cellectis, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "C" | Cellectis-related inventors


Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system

The present invention relates to methods of developing genetically engineered, preferably non-alloreactive t-cells for immunotherapy. This method involves the use of rna-guided endonucleases, in particular cas9/crispr system, to specifically target a selection of key genes in t-cells. ... Cellectis

Large volume ex vivo electroporation method

An object of the invention is to provide an electroporation method for treating vesicles with exogenous material for insertion of the exogenous material into the vesicles which includes the steps of: a. Retaining a suspension of the vesicles and the exogenous material in a treatment volume in a chamber which includes electrodes, wherein the chamber has a geometric factor (cm−1 ) defined by the quotient of the electrode gap squared (cm2) divided by the chamber volume (cm3), wherein the geometric factor is less than or equal to 0.1 cm−1, wherein the suspension of the vesicles and the exogenous material is in a medium which is adjusted such that the medium has conductivity in a range spanning 50 microsiemens/cm to 500 microsiemens/cm, wherein the suspension is enclosed in the chamber during treatment, and b. ... Cellectis

Chimeric antigen receptors with integrated controllable functions

The present invention relates to the field of cell immunotherapy and more particularly to a new generation of chimeric antigen receptors (car), allowing the control of immune cells endowed with such cars through the interaction with small molecules. More particularly, the present invention relates to chimeric antigen receptor which comprise in at least one ectodomain a molecular switch turning the antigen binding function of the receptor from an off to on state, and vice versa. ... Cellectis

Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation

Methods of developing genetically engineered immune cells for immunotherapy, which can be endowed with chimeric antigen receptors targeting an antigen marker that is common to both the pathological cells and said cd38 immune by the fact that the genes encoding said markers are inactivated in said immune cells by a rare cutting endonuclease such as talen, cas9 or argonaute.. . ... Cellectis

Method for in situ inhibition of regulatory t cells

The present invention pertains to engineered t-cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered t-cells of the invention are designed to express both a chimeric antigen receptor (car) directed against at least one antigen expressed at the surface of a malignant or infected cell, and a secreted inhibitor of regulatory t-cells (treg). ... Cellectis

Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells

Methods of developing genetically engineered immune cells for immunotherapy, which can be endowed with chimeric antigen receptors targeting an antigen marker that is common to both the pathological cells and said immune cells (ex: cd38, cs1 or cd70) by the fact that the genes encoding said markers are inactivated in said immune cells by a rare cutting endonuclease such as talen, cas9 or argonaute.. . ... Cellectis

Methods for improving functionality in nk cell by gene inactivation using specific endonuclease

The present invention relates to methods for improving therapeutic activity of nk cell, such as their cytotoxic/cytolytic activity, to be used in immunotherapy, by gene editing. In particular, these methods comprise a step of reduction or inactivation of gene expression using specific endonuclease such as tal-nuclease, crispr or argonaute. ... Cellectis

Cd123 specific multi-chain chimeric antigen receptor

The present invention relates to a new generation of chimeric antigen receptors (car) referred to as multi-chain cars, which are made specific to the antigen cd123. Such cars aim to redirect immune cell specificity and reactivity toward malignant cells expressing the tumor antigen cd123. ... Cellectis

T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm

The present invention relates to a tcr ko—or tcr ko and dck ko—engineered immune cells expressing a chimeric antigen receptors (car) specific for cd123 that is a recombinant chimeric protein able to redirect immune cell specificity and reactivity toward cd123-expressing cells, and more particularly in which extracellular ligand binding is a scfv derived from a cd123 monoclonal antibody, conferring specific immunity against cd123 positive cells. The engineered immune cells endowed with such cd123 cars are particularly suited for treating relapse refractory aml and blastic plasmacytoid dendritic cell neoplasm and for use as a treatment before bone marrow transplantation.. ... Cellectis

Inhibitory chimeric antigen receptors

The invention relates to an inhibitory chimeric antigen receptor (n-car) comprising an extracellular domain comprising an antigen binding domain, a transmembrane domain, and, an intracellular domain wherein the intracellular domain comprises an immunoreceptor tyrosine-based switch motif itsm, wherein said itsm is a sequence of amino acid tx1yx2x3x4, wherein x1 is an amino acid x2 is an amino acid x3 is an amino acid and x4 is v or. . ... Cellectis

Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy

Methods for developing engineered t-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying t-cells by inactivating both genes encoding target for an immunosuppressive agent and t-cell receptor, in particular genes encoding cd52 and tcr. ... Cellectis

Anti-cll1 specific single-chain chimeric antigen receptors (sccars) for cancer immunotherapy

The present invention relates to chimeric antigen receptors (car) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward cll1 positive cells. The engineered immune cells endowed with such cars are particularly suited for immunotherapy for treating cancer, in particular leukemia.. ... Cellectis

Cll1-specific multi-chain chimeric antigen receptor

The present invention relates to a new generation of chimeric antigen receptors (car) referred to as multi-chain cars, which are made specific to the antigen cll1. Such cars aim to redirect immune cell specificity and reactivity toward malignant cells expressing the tumor antigen cll1. ... Cellectis

Anti-hsp70 specific chimeric antigen receptors (cars) for cancer immunotherapy

The present invention relates to chimeric antigen receptors (car) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scfv derived from an anti-hsp70 monoclonal antibody, conferring specific immunity against hsp70 positive cells. The engineered immune cells endowed with such cars are particularly suited for treating in particular leukemia.. ... Cellectis

12/21/17 / #20170360835

Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells

A method of expanding tcralpha deficient t-cells by expressing ptalpha or functional variants thereof into said cells, thereby restoring a functional cd3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary t-cells from donors. ... Cellectis

10/12/17 / #20170292118

Method for modulating car-induced immune cells activity

The present invention relates to a method to modulate the level of activation of an engineered immune cell (such as a chimeric antigen receptor t-cell) for immunotherapy. The present invention also relates to cells obtained by the present method, preferably comprising said modulable/tunable chimeric antigen receptors for use in therapeutic or prophylactic treatment.. ... Cellectis

10/05/17 / #20170283497

Ror1 (ntrkr1) specific chimeric antigen receptors for cancer immunotherapy

The present invention relates to chimeric antigen receptors (car) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scfv derived from a ror1 monoclonal antibody, conferring specific immunity against ror1 positive cells. The engineered immune cells endowed with such cars are particularly suited for treating lymphomas and leukemia, and for solid tumors such as breast, colon, lung, and kidney tumors. ... Cellectis

09/28/17 / #20170275374

Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy

The present invention relates to chimeric antigen receptors (car) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scfv derived from a 5t4 monoclonal antibody, conferring specific immunity against 5t4 positive cells. The engineered immune cells endowed with such cars are particularly suited for treating lymphomas and leukemia, and for solid tumors such as colon, stomach, and ovarian tumors.. ... Cellectis

09/14/17 / #20170260513

Tevi chimeric endonuclease and their preferential cleavage sites

The present invention relates to a method to cleave target nucleic acid sequence by the catalytic domain of a giy-yig homing endonucleases i-tevi. More precisely, the invention relates to the deciphering of new preferential i-tevi cleavage sites for efficient and specific cleavage activity. ... Cellectis

09/14/17 / #20170258024

Potatoes with reduced cold-induced sweetening

Materials and methods are provided for making plants (e.g., solanum varieties) with decreased accumulation of reducing sugars and acrylamide in cold-stored potatoes, specifically, by making tale-nuclease-induced mutations in genes encoding vacuolar invertase.. . ... Cellectis

08/10/17 / #20170226183

Ror1 specific multi-chain chimeric antigen receptor

The present invention relates to a new generation of chimeric antigen receptors (car) referred to as multi-chain cars, which are made specific to the antigen ror1. Such cars aim to redirect immune cell specificity and reactivity toward malignant cells expressing the tumor antigen ror1. ... Cellectis

07/13/17 / #20170198306

Engineering mammalian genome using dna-guided argonaute interference systems (dais)

This invention relates to materials and methods for gene editing in mammalian cells, and more particularly to methods for gene editing using dna-guided argonaute (ago) interference systems (dais) in t-cells.. . ... Cellectis

06/29/17 / #20170183418

Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy

The present invention relates to chimeric antigen receptors (car) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scfv derived from a bcma monoclonal antibody, conferring specific immunity against bcma positive cells. The engineered immune cells endowed with such cars are particularly suited for treating lymphomas, multiple myeloma and leukemia.. ... Cellectis

06/29/17 / #20170183413

Cd123 specific chimeric antigen receptors for cancer immunotherapy

The present invention relates to chimeric antigen receptors (car) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scfv derived from a cd123 monoclonal antibody, conferring specific immunity against cd123 positive cells. The engineered immune cells endowed with such cars are particularly suited for treating lymphomas and leukemia.. ... Cellectis

03/23/17 / #20170081672

Modifying messenger rna stability in plant transformations

Materials and methods for genome engineering through transient expression of a targeted nuclease are described herein. For example, the methods described herein can include introducing into a cell a messenger rna (mrna) that encodes a nuclease targeted to a selected sequence within the cell, where the stability of the mrna is modified by the addition of untranslated regions (utrs).. ... Cellectis

03/16/17 / #20170073423

Method of engineering multi-input signal sensitive t cell for immunotherapy

The present invention relates to a method to engineer immune cell for immunotherapy. In particular said immune cells are engineered with chimeric antigen receptors, which be activated by the combination of hypoxia and ligand extracellular binding as input signals. ... Cellectis

03/09/17 / #20170067022

Method for in situ inhibition of regulatory t cells

The present invention pertains to engineered t-cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered t-cells of the invention are designed to express both a chimeric antigen receptor (car) directed against at least one antigen expressed at the surface of a malignant or infected cell, and a secreted inhibitor of regulatory t-cells (treg). ... Cellectis

02/23/17 / #20170051037

Cs1 specific multi-chain chimeric antigen receptor

The present invention relates to a new generation of chimeric antigen receptors (car) referred to as multi-chain cars, which are made specific to the antigen cs1. Such cars aim to redirect immune cell specificity and reactivity toward malignant cells expressing the tumor antigen cs1. ... Cellectis

02/09/17 / #20170035866

Method for generating immune cells resistant to arginine and/or tryptophan depleted microenvironment

The present invention pertains to engineered immune cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered immune cells of the present invention are characterized in that at least one gene selected from a gene encoding gcn2 and a gene encoding prdm1 is inactivated or repressed. ... Cellectis

01/19/17 / #20170016025

Method for generating t-cells compatible for allogenic transplantation

The present invention pertains to engineered t-cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered t-cells of the invention are characterized in that the expression of beta 2-microglobulin (b2m) and/or class ii major histocompatibility complex transactivator (ciita) is inhibited, e.g., by using rare-cutting endonucleases able to selectively inactivating by dna cleavage the gene encoding b2m and/or ciita, or by using nucleic acid molecules which inhibit the expression of b2m and/or ciita. ... Cellectis








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Cellectis in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cellectis with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###